James Yi Li

Counsel

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

James Yi Li is patent litigator proficient in a diverse range of technologies. His practice focuses on life sciences patent litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act, including contested matters involving chemistry, pharmaceuticals, and biotechnology. James also has experience litigating software and consumer electronics patents in both district court and inter partes review. 

James received his law degree from Harvard Law School, cum laude, in 2015. He graduated from the University of Michigan with a B.S.E. in Biomedical Engineering, summa cum laude, and a Master of Engineering in Pharmaceutical Engineering.



Admissions

Bar Admissions

  • New York

Registered to Practice

  • US Patent & Trademark Office

Education

  • Harvard Law School, J.D., cum laude
  • University of Michigan, M.Eng., Pharmaceutical Engineering
  • University of Michigan, B.S.E., Biomedical Engineering, summa cum laude

Professional Activities

Publications

  • Co-Author, “AI and Life Sciences Patents: Separating Myth From Reality,” New York Law Journal (March 20, 2020)
  • Co-Author (Yu J, Yu J, Mani RS, et al.), “An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression,” Cancer Cell. 2010, 17(5):443-454.

Speaker

  • “Paragraph IV Patent Protection and Litigation: Addressing the Complex Challenges,” The Knowledge Group (October 3, 2019)
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of chemotherapy induced nausea
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of multiple myeloma
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of heart failure 
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of irritable bowel syndrome
  • Represented international pharmaceutical company on patents related to treatment of ovarian cancer
VIEW MORE

Press Releases